Meclizine

證據等級: L5

預測適應症: 6 個

Meclizine: From Motion Sickness / Vertigo to Allergic Urticaria

One-Sentence Summary

Meclizine is a first-generation H1 antihistamine, classically used to treat motion sickness, vertigo, and associated nausea and vomiting. The TxGNN model predicts it may be effective for Allergic Urticaria, which is mechanistically plausible as H1 antagonists are first-line therapy for urticaria as a class — however, there are 0 clinical trials and 0 publications directly supporting this specific use of Meclizine, and clinical preference has shifted to second-generation non-sedating antihistamines.

Quick Overview

Item	Content
Original Indication	Motion sickness; Vertigo-associated nausea and vomiting
Predicted New Indication	Allergic Urticaria
TxGNN Prediction Score	99.67%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not formally available in this evidence pack. Based on established pharmacological knowledge, Meclizine is a first-generation H1 receptor antagonist with additional anticholinergic properties. It suppresses the vestibular system and central histamine signalling, explaining its efficacy in motion sickness and vertigo-related nausea.

Allergic urticaria is driven by mast cell degranulation and histamine release, with H1 receptor blockade serving as the universally accepted first-line mechanism. In this sense, TxGNN’s prediction reflects a valid class-effect mechanistic link: blocking H1 receptors directly counters the wheal-and-flare cascade underlying urticaria. The transition from vestibular/CNS histamine blockade (motion sickness) to peripheral H1 blockade (urticaria) represents a shift in target organ, not a change in core mechanism.

That said, clinical guidelines for urticaria have firmly moved toward second-generation, non-sedating H1 antihistamines (cetirizine, loratadine, fexofenadine, bilastine) due to superior tolerability and absence of CNS sedation. Meclizine’s pronounced sedating and anticholinergic side effects make it a poor candidate for the chronic, long-term management that urticaria typically requires. No independent clinical studies specifically evaluate Meclizine for allergic urticaria, and this prediction is best understood as a class-level signal rather than a compound-specific opportunity.

Clinical Trial Evidence

Currently no related clinical trials registered for allergic urticaria.

Note: One trial was identified in the broader evidence sweep (NCT01537471) but is associated with the common cold query and investigates Pre-Pulse Inhibition (a neuropsychiatric biomarker) — it has no relevance to allergic urticaria and is excluded here.

Literature Evidence

Currently no related literature available for allergic urticaria.

India Market Information

Meclizine currently has no registered products in India. The drug is not marketed and holds zero approved licenses with CDSCO. Any introduction for a new indication would require a full new drug application process from the ground up.

Safety Considerations

Drug Interactions (252 total interactions identified; top interactions listed below):

Severity	Interacting Drug	Clinical Concern
Major	Potassium citrate	Significant interaction — monitor closely
Major	Potassium chloride	Significant interaction — monitor closely
Moderate	Hyoscyamine	Additive anticholinergic effects (dry mouth, urinary retention, constipation)
Moderate	Atropine	Additive anticholinergic effects
Moderate	Glycopyrronium	Additive anticholinergic effects
Moderate	Glycopyrronium (topical)	Additive anticholinergic effects
Moderate	Dicyclomine	Additive anticholinergic effects
Moderate	Methscopolamine	Additive anticholinergic effects
Moderate	Mepenzolate	Additive anticholinergic effects
Moderate	Clidinium	Additive anticholinergic effects
Moderate	Trospium	Additive anticholinergic effects
Moderate	Morphine	Risk of enhanced CNS/respiratory depression
Moderate	Morphine (liposomal)	Risk of enhanced CNS/respiratory depression
Moderate	Opium	Risk of enhanced CNS/respiratory depression
Moderate	Nabilone	Additive CNS depressant effects
Moderate	Metoclopramide	Opposing effects on GI motility; reduced metoclopramide efficacy
Moderate	Loperamide	Additive GI motility reduction
Moderate	Eluxadoline	Additive GI effects
Moderate	Eliglustat	Interaction potential
Moderate	Glycerol phenylbutyrate	Interaction potential

Package insert warnings and contraindications are not currently available (data gap DG001). Please refer to the official prescribing information before clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: Although Meclizine’s H1 antagonism provides a mechanistically coherent basis for allergic urticaria, there is a complete absence of direct clinical evidence for this specific drug in this indication, clinical guidelines actively prefer second-generation antihistamines, and the drug holds zero market authorisations in India — making a near-term repurposing pathway impractical without substantial additional investigation.

To proceed, the following is needed:

Direct clinical evidence (even pilot or observational studies) comparing Meclizine to second-generation antihistamines in allergic urticaria
Identification of a specific patient subgroup where Meclizine’s sedating or anticholinergic profile might confer a clinical advantage (e.g., urticaria with concurrent sleep disturbance)
Formal MOA documentation from DrugBank (data gap DG002 — currently unresolved)
Retrieval of CDSCO package insert for complete warnings and contraindications (data gap DG001 — blocking severity)
Market feasibility analysis for India entry given zero existing regulatory footprint
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.